The Broad Institute, Inc.

The Broad Institute, Inc., doing business as Broad Institute of MIT and Harvard, is a non-profit biomedical and genomic research organization providing whole-genome sequencing, computational biology, precision medicine data infrastructure, and advanced imaging and biomarker discovery services to the federal research enterprise as a prime grant recipient and contractor. The Broad operates predominantly as a grant recipient (62% of recent awards), particularly across the National Institutes of Health, and competes full-and-open without set-aside designations.

The Broad delivers concrete capabilities grounded in large-scale genomic sequencing, multi-omic analysis, computational biology, and precision medicine infrastructure. Representative work includes a $500 million single-award IDIQ with the National Heart, Lung and Blood Institute for the Trans-Omics for Precision Medicine (TOPMed) Centralized Omics Resource, under which the Broad issued four delivery orders totaling $64.6 million through September 2030 for genomic sequencing, analysis, and data management supporting precision medicine research; a $12.7 million FY2026 delivery order from NHLBI for continued TOPMed CORE support through September 2027 on a firm fixed price basis; and a $215,100 purchase order from the National Institute on Aging awarded September 2026 for whole genome sequencing of 600 samples from the Healthy Aging in Neighborhoods of Diversity across the Life Span study using NovaSeq X-Plus sequencing with 150 bp paired-end runs at minimum 30x coverage and DRAGEN Germline pipeline analysis. Grant work spans federal research in neurodegenerative disease, cancer biology, immunology, metabolomics, and structural genetics; recent recipients include a $3.312 million cooperative agreement from the National Institute of Mental Health to develop and validate cell-type-specific enhancers for neuromodulatory neuron subtypes, a $2.427 million NIMH cooperative agreement to establish and operate the NIMH Genomics Consortium Coordination Center, and a $1.647 million NIDDK grant for massive-scale genomic risk assessment across monogenic and common forms of diabetes involving sub-awards to four partner universities.

Customer concentration sits heavily with NIH institutes. The top five funding agencies account for 52% of recent awards by count: the National Cancer Institute (118 awards, $255.1 million), the National Heart, Lung and Blood Institute (87 awards, $1.31 billion), the NIH Office of the Director (74 awards, $4.4 million), the National Institute of Mental Health (73 awards, $149 million), and the National Institute of Allergy and Infectious Diseases (69 awards, $7.6 million). By potential value, the concentration is starker: NHLBI alone anchors 70% of combined potential value across the top five customers, driven by the $500 million TOPMed CORE parent contract and associated delivery orders. The Broad also holds work with the Department of Defense (Defense Health Agency, Defense Advanced Research Projects Agency), the Department of Veterans Affairs, the Centers for Disease Control and Prevention, and the National Institutes of Health Office of the Director's programs in trans-NIH research support and the Human Virome Program.

The Broad's vehicle position centers on large-scale NIH infrastructure contracts and grant vehicles. Beyond the $500 million TOPMed CORE indefinite delivery contract with NHLBI, the Broad holds a single-award indefinite delivery contract with the Veterans Integrated Service Network 21 (ceiling $200,908.50) for prostate cancer-specific sequencing research services through June 2029. The Broad also operates as a prime recipient on multiple NIH cooperative agreements and project grants that carry multi-year funding authority and sub-award relationships with academic medical centers and research universities.

Activity trajectory shows sustained engagement with recent volatility. Awards per year ran 71 (2022), 62 (2023), 122 (2024), 98 (2025), and 64 (2026 year-to-date), reflecting both grant funding cycles and contract award timing. Ninety-two awards with ultimate completion dates in the next twenty-four months carry combined potential value of $160.8 million, representing recompete exposure for the Broad and recompete opportunity for competitors across sequencing, precision medicine infrastructure, and genomic analysis work.

SCI-reported service contract invoicing totaled $52.1 million across FY2022–FY2025 (prime contracts only), with annual variation: FY2022 $21 million across 13.9 FTEs, FY2023 $9.3 million across 2.1 FTEs, FY2024 $21.8 million across 14.2 FTEs, and FY2025 $1 million across 1 FTE. These figures are a strict subset of the Broad's federal services activity; they exclude grant revenue, goods, and products, and represent only contracts above the $150,000 reporting threshold. Government-paid hourly rates on federal services contracts captured in SCI ranged from a 10th percentile of $115.81/hr to a median of $1,073.67/hr and a 90th percentile of $4,121.40/hr, reflecting a mix of technical labor and senior scientific consultation. The Broad performed 0% of contractor hours through subcontractors on SCI-reportable prime contracts, indicating delivery of work through its own staff.

The Broad operates as a subcontractor to other research institutions on grant work; sub-awards show the Broad providing metabolomics analysis, genomic sequencing and bioinformatics, gene editing strategy and computational analysis, and spatial transcriptomics support to prime recipients including Dana-Farber Cancer Institute, the Children's Hospital Corporation, the Washington University, Jackson Laboratory, and the University of California system. The Broad also receives sub-awards from academic partners for shared services such as the Metabolomics Platform (operating under the direction of Dr. Clary Clish) and the Genomics Platform, which deliver mass spectrometry-based metabolite profiling and whole-genome sequencing to consortium projects across multiple NIH institutes.

Corporate structure includes Broad Clinical Laboratories, LLC, a subsidiary not-for-profit organization, reflecting the Broad's diagnostic and testing capabilities integrated with its research mission.